Esperion Therapeutics (ESPR) Projected to Post Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) is anticipated to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Esperion Therapeutics to post earnings of $0.16 per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 9:30 AM ET.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $3.34 on Tuesday. The company’s fifty day moving average is $3.53 and its two-hundred day moving average is $3.06. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18. The stock has a market capitalization of $798.47 million, a price-to-earnings ratio of -6.68, a price-to-earnings-growth ratio of 0.73 and a beta of 1.09.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ESPR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler assumed coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price on the stock. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Finally, Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Insiders Place Their Bets

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at $1,715,816.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 15,543 shares of company stock worth $55,709. Insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently bought and sold shares of the business. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $25,000. Kestra Advisory Services LLC acquired a new position in Esperion Therapeutics in the 4th quarter worth about $35,000. Captrust Financial Advisors acquired a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $40,000. CIBC Bancorp USA Inc. bought a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $56,000. Finally, Cibc World Markets Corp acquired a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $57,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.